Barclays’s Carisma Therapeutics CARM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-100
| Closed | -$39 | – | 5505 |
|
|
2025
Q2 | $39 | Sell |
100
-549,205
| -100% | -$147K | ﹤0.01% | 5125 |
|
|
2025
Q1 | $170K | Hold |
549,305
| – | – | ﹤0.01% | 4142 |
|
|
2024
Q4 | $230K | Hold |
549,305
| – | – | ﹤0.01% | 4242 |
|
|
2024
Q3 | $539K | Buy |
549,305
+549,290
| +3,661,933% | +$595K | ﹤0.01% | 3728 |
|
|
2024
Q2 | $23 | Sell |
15
-18,655
| -100% | -$27.8K | ﹤0.01% | 4777 |
|
|
2024
Q1 | $42.4K | Sell |
18,670
-17,928
| -49% | -$43.1K | ﹤0.01% | 4648 |
|
|
2023
Q4 | $107K | Buy |
36,598
+31,726
| +651% | +$94.3K | ﹤0.01% | 4622 |
|
|
2023
Q3 | $20.6K | Sell |
4,872
-440
| -8% | -$2.79K | ﹤0.01% | 4174 |
|
|
2023
Q2 | $46.6K | Buy |
+5,312
| New | +$28.9K | ﹤0.01% | 3868 |
|
|
2022
Q2 | – | Sell |
-1,634
| Closed | -$19K | – | 5038 |
|
|
2022
Q1 | $19K | Sell |
1,634
-10,583
| -87% | -$148K | ﹤0.01% | 4459 |
|
|
2021
Q4 | $199K | Buy |
12,217
+8,055
| +194% | +$162K | ﹤0.01% | 3565 |
|
|
2021
Q3 | $66K | Buy |
4,162
+2,952
| +244% | +$142K | ﹤0.01% | 4046 |
|
|
2021
Q2 | $112K | Sell |
1,210
-6,322
| -84% | -$403K | ﹤0.01% | 3802 |
|
|
2021
Q1 | $392K | Buy |
+7,532
| New | +$355K | ﹤0.01% | 3326 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6154 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6370 |
|
|
2019
Q3 | – | Sell |
-10
| Closed | – | – | 6731 |
|
|
2019
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 6953 |
|
|
2019
Q1 | $0 | Buy |
+10
| New | +$173 | ﹤0.01% | 7029 |
|
|
2018
Q3 | – | Sell |
-1,615
| Closed | -$63K | – | 7133 |
|
|
2018
Q2 | $63K | Buy |
+1,615
| New | +$71.2K | ﹤0.01% | 5519 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 7069 |
|
|
2017
Q4 | – | Sell |
-4
| Closed | – | – | 6933 |
|
|
2017
Q3 | $0 | Buy |
+4
| New | +$112 | ﹤0.01% | 6847 |
|
|
2017
Q1 | – | Sell |
-1
| Closed | – | – | 6761 |
|
|
2016
Q4 | $0 | Buy |
+1
| New | +$44 | ﹤0.01% | 6608 |
|
|
2015
Q2 | – | Sell |
-7
| Closed | -$2K | – | 7018 |
|
|
2015
Q1 | $2K | Sell |
7
-6
| -46% | -$1.31K | ﹤0.01% | 6853 |
|
|
2014
Q4 | $3K | Buy |
13
+5
| +63% | +$1.12K | ﹤0.01% | 7058 |
|
|
2014
Q3 | $2K | Sell |
8
-12
| -60% | -$2.85K | ﹤0.01% | 7387 |
|
|
2014
Q2 | $5K | Buy |
20
+14
| +233% | +$3.46K | ﹤0.01% | 7104 |
|
|
2014
Q1 | $2K | Buy |
+6
| New | +$1.8K | ﹤0.01% | 7391 |
|
Other funds holding CARM
MC
GS
BCM
EF
Barclays's CARM Position: Q3 2025 in Review
Barclays sold out of Carisma Therapeutics (CARM) in Q3 2025, closing a stake of 100 shares — an estimated $39 sold.
Barclays first reported a position in CARM in Q1 2014 and held it in 24 quarters. The position peaked at $539K in Q3 2024. 33 funds tracked by Wall St. Rank hold CARM as of Q3 2025.
- Barclays reported no remaining Carisma Therapeutics position as of Q3 2025 after selling out during the quarter.
- Barclays sold 100 Carisma Therapeutics shares in Q3 2025, an estimated $39.
- Barclays first reported a position in Carisma Therapeutics in Q1 2014 and held it in 24 quarters.
- Barclays's Carisma Therapeutics position peaked at $539K in Q3 2024.
- 33 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.